Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer

J. Bendell, F. Ciardiello, J. Tabernero, N. Tebbutt, C. Eng, M. Di Bartolomeo, A. Falcone, M. Fakih, M. Kozloff, N. Segal, A. Sobrero, Y. Shi, L. Roberts, Y. Yan, I. Chang, A. Uyei, T. Kim

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)v123
JournalAnnals of Oncology
Publication statusPublished - Jun 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this